Arabic Arabic English English French French German German
dark

Transgene Reports Business Update and End Q1 2021 Financial Position

TG4001 – Regulatory clearance received for randomized Phase II trial – First patient expected to be enrolled in 2Q 2021

TG6002 – Initial Phase I data provides clinical proof of concept for the intravenous administration of Transgene’s double deleted VV cop TK-RR- patented virus backbone, the basis of the Invir.IO™ oncolytic virus backbone Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming A Publicly Listed Company To Address Unmet Needs Of Men And Women Through Development Of Androgen And Metabolic Therapies

Next Post

Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease

Related Posts
Total
0
Share